- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
EC Questions Dual Pricing
Pharmaceutical Executive
Brussels, Belgium-Pfizer believes the dual pricing system it introduced in Spain complies with Spanish and European Union competition laws, but the European Commission isn't so sure. Competition policy commissioner Mario Monti says the EC will scrutinize Pfizer's pricing policy, which is intended to prevent parallel trade out of low-cost Spain.
Brussels, Belgium-Pfizer believes the dual pricing system it introduced in Spain complies with Spanish and European Union competition laws, but the European Commission isn't so sure. Competition policy commissioner Mario Monti says the EC will scrutinize Pfizer's pricing policy, which is intended to prevent parallel trade out of low-cost Spain.
The investigation will initially determine whether the policy is similar to GlaxoSmithKline's practice of charging Spanish wholesalers more for medicines destined for export rather than for the home market. The commission ruled against GSK's policy earlier this year.
Colette Graham, Pfizer's European corporate media relations director, refused to comment on whether the company's pricing policy was similar to GSK's. But she said it was based on a price with provision for reduction, adding, "We believe it is consistent with Spanish and EU competition rules."
In a speech at an EC-sponsored competition day conference in Antwerp, Monti said Brussels had pursued a merciless campaign against industries and companies that have sought to prevent parallel trade. However, he said, "The industry is tenacious. And it asks the courts in Luxembourg to declare that the pharmaceutical sector is so different that the commission's parallel trade policy has no raison d'etre.
"Leaving aside the details, we take the view that the industry is wrong: first, in contending that parallel trade in medicines harms consumers and second, in arguing that the commission's policy brings no benefits at all for consumers in the high-price countries."
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
To Tackle the Plastic Waste Crisis in Pharma, Here’s Where to Start
October 30th 2024By demonstrating big advancements in recycling, pharma companies will be much more likely to attract shareholders and other investors, giving themselves a leg up in the competition to lead the biopharmaceutical industry well into the future.
